Carpal Tunnel Syndrome

Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy, resulting from compression of the median nerve as it traverses the carpal tunnel at the wrist. Synonyms include median neuropathy at the wrist, median nerve entrapment syndrome, and the historical term tardy median palsy. The abbreviation CTS is universally accepted. CTS is the most frequent upper-limb surgical diagnosis in the United States, with over 500,000 carpal tunnel releases performed annually ^[1]B2b, and it imposes substantial morbidity on affected individuals.

Definition and Anatomic Basis

The carpal tunnel is a rigid osteofibrous canal bounded by the carpal bones dorsally and the transverse carpal ligament (flexor retinaculum) volarly. Within it lie the median nerve and nine flexor tendons. Any process that reduces tunnel volume or increases its contents elevates interstitial pressure, compromising median nerve perfusion and axonal transport. The clinical syndrome is defined by characteristic sensory and motor deficits in the median nerve distribution (thumb, index, middle, and radial half of the ring finger) ^[2]A1c.

Classification Systems

Two complementary axes define CTS severity: clinical staging and electrophysiologic grading. Both are essential for treatment stratification and prognosis.

Clinical severity follows a progressive pattern:

• Mild: Intermittent paresthesias, nocturnal symptoms, no sensory loss or motor weakness.
• Moderate: Persistent sensory loss, thenar weakness without atrophy.
• Severe: Thenar atrophy, fixed sensory deficit, and possible autonomic changes ^[2]A1c.

Electrophysiologic severity is graded by nerve conduction studies (NCS) and electromyography (EMG). A commonly used three-tier system, consistent with the grading converted in ^[4]D5, is:

• Mild: Prolonged sensory latency or reduced sensory amplitude across the wrist.
• Moderate: Prolonged motor latency with preserved compound muscle action potential (CMAP).
• Severe: Absent sensory response, prolonged or absent motor response, and/or denervation potentials (fibrillations, positive sharp waves) on needle EMG ^[4]D5.

More granular scales exist (e.g., Bland classification grades 1-6), but the three-tier system correlates well with surgical decision-making: moderate-to-severe electrophysiologic disease is a strong indication for surgery ^[4]D5.

Etiological Classification

CTS is classified by underlying cause into three broad categories:

Diabetes is a particularly strong risk factor: poor glycemic control (elevated HbA1c) correlates with more severe CTS ^[7]B2b. Occupational mechanical exposures, including repetitive motion and vibration, increase CTS risk with moderate evidence ^[6]B2a.

Clinical Significance

CTS affects approximately 1-3% of the general population, with lifetime risk approaching 10%. It is the leading cause of work-related hand disability and accounts for the highest number of days lost among upper-extremity disorders. Accurate diagnosis and severity classification are critical because mild disease often responds to conservative measures, whereas moderate-to-severe disease typically requires surgical release to prevent irreversible nerve damage ^[2]A1c[4]D5.

Pearl: Carpal tunnel syndrome is defined by characteristic symptom distribution and confirmed by electrodiagnostic testing; severity grading (mild, moderate, severe) guides treatment decisions, with moderate-to-severe cases often requiring surgical release ^[2]A1c[4]D5.

The core pathogenic mechanism of carpal tunnel syndrome (CTS) is chronic compression of the median nerve within the osteofibrous carpal tunnel, initiating a cascade of vascular compromise, intraneural edema, demyelination, and ultimately axonal loss. This sequence links every risk factor and clinical feature to a measurable tissue injury.

Stepwise Pathogenic Cascade

1. Ischemic nerve injury. External pressure exceeding 20-30 mm Hg impairs epineurial venular flow, causing venous congestion and intrafascicular edema [^[22]A1b, PMID:39765427]. Initially reversible, this ischemia produces intermittent paresthesias, the hallmark early symptom.

2. Intraneural edema and fibrosis. Sustained or recurrent compression disrupts the blood-nerve barrier, leading to endoneurial edema. Over time, fibroblasts deposit collagen, transforming the nerve into a less compliant structure. Manual lymphatic drainage can reduce intraneural edema in mild-to-moderate CTS, confirming this as a modifiable early step [^[22]A1b, PMID:39765427].

3. Demyelination. Chronic pressure (typically >30 mm Hg sustained) causes segmental demyelination of large, myelinated sensory fibers. This slows nerve conduction velocity, the electrodiagnostic hallmark of CTS, and produces the classic prolonged sensory latencies.

4. Axonal degeneration. Persistent compression exceeding 40-50 mm Hg or lasting months to years leads to Wallerian-like degeneration of the most severely affected axons, beginning with large sensory fibers and progressing to motor axons. This irreversible step correlates with thenar atrophy, persistent numbness, and fixed motor deficits.

Tissue Tolerance and Failure Mode

The carpal tunnel is a rigid compartment bounded by the carpal bones dorsally and the transverse carpal ligament volarly. Its volume (approximately 5-6 mL in adults) is fixed; the flexor tendons and median nerve occupy roughly 75% of that volume at rest, with little reserve. Any process that increases the volume of tunnel contents (tenosynovial hypertrophy, edema, space-occupying lesion) or reduces tunnel dimensions (wrist flexion/extension, distal radius fracture malunion) raises hydrostatic pressure and triggers the cascade above.

Tissue tolerance is governed by three variables:

• Magnitude of pressure: Pressures >30 mm Hg reduce intraneural blood flow; >40 mm Hg produces ischemic conduction block.
• Duration: Intermittent paresthesias are reversible if decompression occurs within hours; once axonal loss begins (weeks to months), recovery is incomplete.
• Frequency: Repeated peaks of pressure (e.g., during sleep with wrist flexion) cause cumulative microtrauma even if baseline pressure is normal.

Molecular and Environmental Modifiers

Diabetes and the AGE-RAGE axis. In diabetic patients, advanced glycation end products (AGEs) accumulate in flexor tendon synovium. Receptor for AGEs (RAGE) is overexpressed in the synovium of diabetic CTS patients and correlates with electrophysiologic severity [^[20]B3b, PMID:41369568]. RAGE activation drives pro-inflammatory cytokine release (TNF-α, IL-6), promoting fibroplasia and further elevating tunnel pressure.

Amyloid deposition. Transthyretin-mediated (ATTR) amyloidosis, both wild-type and hereditary, is an underrecognized cause of CTS, especially in older men. Amyloid fibrils deposit in the transverse carpal ligament, the flexor tenosynovium, and the median nerve itself, producing bilateral, often severe, neuropathy that may precede systemic manifestations by years [^[25]B2a, PMID:37740174].

Systemic fluid shifts. Pregnancy, hypothyroidism, and renal failure all increase interstitial fluid volume within the tunnel, raising hydrostatic pressure and triggering CTS in anatomically predisposed individuals.

Biomechanics: Why the Carpal Tunnel Fails in Motion

The median nerve is not a static cable; it glides and deforms within the tunnel during wrist and finger motion. During full finger flexion, the median nerve translates radially and volarly, and its cross-sectional area increases by up to 15% [^[12]C4, PMID:19952256]. In CTS patients, this adaptive mobility is lost due to perineural adhesions and synovial fibrosis, resulting in nerve tethering. The tethered nerve is subjected to increased tensile strain during motion, compounding the compressive insult. This explains why many patients report symptom exacerbation with gripping, driving, or holding a phone, activities that combine wrist flexion with high tendon excursion.

The Biopsychosocial Layer

While the pathophysiology above is purely mechanical and molecular, patient-reported symptoms and disability are powerfully modulated by psychological factors. Kinesiophobia (fear of movement) and catastrophic thinking correlate more strongly with upper-extremity-specific disability than electrodiagnostic severity [^[11]C4, PMID:23283376]. Similarly, general anxiety (GAD-7 score) is independently associated with problematic recovery after carpal tunnel release, even after controlling for neuropathy severity [^[18]B2b, PMID:35023866]. Surgeons who rely solely on the reported magnitude of incapability rather than objective signs of neuropathy may overestimate disease severity, leading to unnecessary surgery for mild or physiologic median neuropathy [^[17]C4, PMID:34817441].

Anatomic Susceptibility Factors

• Wrist ratio: A square-shaped wrist (increased depth-to-width ratio) reduces tunnel volume and is associated with higher baseline pressures.
• Congenitally small tunnel: Rare, but a small carpal canal can be the sole cause of familial CTS, particularly in young women with no other risk factors.
• Anatomic anomalies: A persistent median artery, a bifid median nerve, or anomalous muscle bellies (e.g., palmaris profundus) further crowd the tunnel.
• Thenar muscle aberrations: Anomalous insertion of the thenar muscles can compress the median nerve during thumb opposition [^[16]B3b, PMID:24777728].

Pearl: The progression from intermittent, reversible paresthesia to fixed numbness and thenar atrophy is a linear biologic cascade of ischemia → edema → demyelination → axonal loss; early diagnosis (before stage 3) offers the best chance of full recovery, while stages 3 and 4 represent irreversible structural nerve injury [^[22]A1b, PMID:39765427][^[13]D5, PMID:30973521].

Carpal tunnel syndrome is the most prevalent peripheral nerve entrapment neuropathy, with incidence rising in aging populations ^[37]A1a. While precise population-based incidence rates vary by diagnostic criteria, the condition accounts for a substantial proportion of hand surgery referrals. The lifetime risk of developing CTS is increased in women, particularly those undergoing hysterectomy with ovarian conservation before natural menopause , suggesting a hormonal component ^[40]B2b. Age is a strong independent risk factor; patients aged 70 years and older represent a growing demographic undergoing carpal tunnel release with comparable efficacy to younger cohorts ^[37]A1a.

Risk Factors

Multiple modifiable and non-modifiable factors contribute to CTS risk. Diabetes mellitus is a well-established risk factor; a family history of diabetes in first-degree relatives also increases the risk of CTS, indicating a genetic predisposition independent of overt diabetes ^[5]B2b. Obesity, hypothyroidism, rheumatoid arthritis, and pregnancy are commonly cited risk factors, though specific odds ratios from the provided references are limited.

Systemic amyloidosis is an important underrecognized cause of CTS, particularly in older adults with bilateral involvement. In a large cohort of patients with bilateral CTS, 0.95% had concomitant amyloidosis ^[39]B2b. Tenosynovial biopsy at the time of carpal tunnel release can identify amyloid deposition, and a predictive nomogram incorporating age, sex, and comorbidities can guide screening ^[30]B2b. CTS often precedes other manifestations of systemic amyloidosis by years, making it a potential early marker for cardiac and renal complications ^[39]B2b.

Fibrotic diseases co-occur with CTS, suggesting shared pathophysiologic pathways involving extracellular matrix dysregulation ^[38]B2b. This association may explain the increased risk of CTS in conditions such as Dupuytren contracture and trigger finger.

Risk Factor Table

Temporal Trends

The incidence of CTS is increasing, particularly in older populations, likely due to aging demographics and increased recognition ^[37]A1a. No seasonal variation is reported in the provided literature.

Special Considerations

Amyloidosis-associated CTS is a distinct entity that warrants consideration in older patients with bilateral symptoms, as it may herald systemic disease ^{[30]B2b[39]B2b}. No vaccine-related risk for CTS has been identified in the provided references.

Pearl: Carpal tunnel syndrome is the most common entrapment neuropathy with rising incidence in aging populations; bilateral CTS in older adults should prompt consideration of systemic amyloidosis, as early detection can improve cardiovascular and renal outcomes ^{[37]A1a[39]B2b}.

The classic presentation of carpal tunnel syndrome follows a predictable sequence: nocturnal paresthesias in the median nerve distribution, progressing to persistent sensory loss and then thenar weakness. Symptoms typically begin insidiously, often in the dominant hand, and may be bilateral in up to 60% of patients ^[53]D5. The hallmark is nocturnal awakening with numbness or tingling in the thumb, index, middle, and radial half of the ring finger, a symptom with a sensitivity of 77.4% for confirmed CTS ^[57]B2b. Patients often report shaking the hand (the "flick sign") to relieve symptoms. As the condition advances, paresthesias become diurnal and are provoked by sustained grip, wrist flexion, or repetitive hand use ^[52]A1c. Pain, when present, is typically a dull ache in the thenar region or forearm; pain without numbness is not characteristic of CTS and should prompt consideration of alternative diagnoses ^[36]C4.

Neurological Examination Findings

Sensory examination should assess light touch, two-point discrimination, and monofilament testing in the median nerve distribution. Static two-point discrimination >6 mm indicates advanced sensory loss and correlates with poorer surgical outcomes ^[53]D5. Motor examination focuses on thumb abduction (abductor pollicis brevis) and opposition. Thenar atrophy is a late sign and suggests chronic severe compression ^[51]C4. Provocative tests remain the bedside mainstay: the Phalen test (wrist flexion for 60 seconds) has a sensitivity of 52.8% , and the Tinel sign (percussion over the carpal tunnel) has a sensitivity of only 37.7% ^[57]B2b. The carpal compression test (direct pressure over the tunnel) may be more sensitive, though data are limited ^[52]A1c. The CTS-6, a validated clinical diagnostic aid, combines symptom distribution, nocturnal symptoms, thenar atrophy, and provocative test results to estimate pretest probability ^[43]C4.

Phenotypic Variants

Red Flags

Acute CTS presents with rapid onset of severe pain, swelling, and sensory loss following trauma or anticoagulation; this is a surgical emergency requiring immediate decompression ^[54]D5. Thenar atrophy or two-point discrimination >10 mm indicates advanced neuropathy and predicts incomplete recovery after release ^[51]C4. Bilateral CTS in an older male, especially with trigger finger or distal biceps rupture, should raise suspicion for systemic amyloidosis; tenosynovial biopsy at the time of release can confirm the diagnosis ^{[30]B2b[55]D5}.

Atypical Presentations

Some patients report only pain in the thenar eminence or forearm without clear sensory symptoms, these cases have a lower pretest probability and often require electrodiagnostic confirmation ^[68]C4. Whole-hand numbness or paresthesias limited to the ulnar digits suggest a differential of cervical radiculopathy or polyneuropathy ^[52]A1c. Psychological factors such as pain catastrophizing and depression can amplify pain intensity and should be assessed when symptoms seem disproportionate to objective findings ^[36]C4.

Pearl: Nocturnal paresthesias in the median nerve distribution are the most sensitive symptom (77.4%), and the combination of symptom distribution and nocturnal awakening is more reliable than any single provocative test for diagnosing carpal tunnel syndrome ^[57]B2b.

The diagnosis of carpal tunnel syndrome (CTS) rests on a structured clinical evaluation supported by confirmatory testing. The clinical history and physical examination remain the initial and most accessible diagnostic instruments, but their accuracy is limited compared to objective testing ^{[57]B2b[72]B3b}. The gold-standard diagnostic test for CTS is electrodiagnostic testing (EDX), specifically, nerve conduction studies (NCS) with or without electromyography (EMG), which confirms median neuropathy at the wrist, grades severity, and excludes other neuropathies ^{[53]D5[71]B3b}. Ultrasonography (US) has emerged as a valid, patient-friendly alternative with comparable accuracy and superior patient tolerance ^{[47]A1a[69]B2b[73]B2c}.

Clinical History and Examination

A focused history yields the highest-yield diagnostic information. Nocturnal awakening with paresthesias in the median nerve distribution (thumb, index, middle, and radial half of the ring finger) has a sensitivity of 77.4% for CTS ^[57]B2b. Patients may report a dull ache in the forearm, or a sense of weakness and clumsiness. The symptom distribution should spare the ulnar-innervated small finger and dorsal thumb (radial sensory nerve territory). Pain without numbness or nocturnal symptoms is atypical and should raise suspicion for alternative diagnoses such as cervical radiculopathy or tendinopathy ^[36]C4.

Two provocative physical examination maneuvers remain standard:

• Phalen maneuver (maximal wrist flexion for 60 seconds): sensitivity 52.8%, specificity variable ^[57]B2b.
• Tinel sign (percussion over the median nerve at the wrist): sensitivity 37.7% ^[57]B2b.

A positive Phalen or Tinel sign supports the diagnosis when present, but their modest sensitivity means a negative test does not exclude CTS. Sensory loss in the median distribution, thenar atrophy, or a positive Durkan compression test (manual pressure over the carpal tunnel) are more specific but less sensitive signs. The CTS-6 (Carpal Tunnel Syndrome 6) is a validated clinical diagnostic tool that combines six weighted criteria (nocturnal paresthesias, positive Tinel/Phalen, thenar atrophy, symptom distribution, and sensory loss) to estimate the probability of CTS; a score ≥12 is considered a strong indication for confirmatory testing ^{[49]C4[69]B2b}.

Gold-Standard Test: Electrodiagnostic Testing (EDX)

Nerve conduction studies (NCS) are the recommended confirmatory test before carpal tunnel release surgery according to the American Academy of Orthopaedic Surgeons (AAOS) ^[73]B2c. The test measures median nerve distal motor latency (DML) and sensory nerve conduction velocity (SNCV) across the carpal tunnel. A prolonged DML (typically >4.0-4.5 ms) or reduced SNCV (<50 m/s) is diagnostic. EDX also allows severity grading using the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) scale: mild (prolonged SNCV only), moderate (prolonged DML with normal thenar EMG), severe (absent sensory response with prolonged DML or denervation on EMG) ^[71]B3b. This grading directly influences treatment decisions (see Severity Stratification section).

EDX has a sensitivity of approximately 80-85% and specificity >95% for CTS when using standard criteria ^[69]B2b. Its main limitation is that it can be falsely normal in early or mild CTS. EDX also helps rule out other causes of hand numbness such as cervical radiculopathy or polyneuropathy.

Imaging: Ultrasonography (US) and MRI

High-resolution ultrasonography (US) is now recognized as a first-line confirmatory test equivalent to EDX for diagnosing CTS ^{[47]A1a[69]B2b[73]B2c}. US measures the cross-sectional area (CSA) of the median nerve at the level of the pisiform bone. A CSA >10-11 mm² is the most commonly used diagnostic threshold ^[71]B3b. The wrist-to-forearm ratio (CSA at wrist divided by CSA at proximal forearm) is another metric with high diagnostic accuracy; a ratio >1.4-1.5 strongly suggests CTS ^[71]B3b.

A 2010 meta-analysis reported a pooled sensitivity of 78% and specificity of 91% for US using an 11 mm² cut-off ^[47]A1a. Subsequent studies using a validated clinical reference standard found US (CSA ≥10 mm²) had a sensitivity of 92% and specificity of 80%, compared to 89% and 80% for EDX, respectively, a statistically non-significant difference ^[69]B2b. Cost-effectiveness analyses support US as a first-line test for general practitioners and specialists when surgery is being considered, as it is less painful, faster, and avoids the discomfort of NCS ^[73]B2c.

Magnetic resonance imaging (MRI) is not routinely indicated for diagnosing idiopathic CTS. Its role is reserved for cases with suspected structural causes (e.g., ganglion cyst, tumor, anomalous muscle) or when evaluating concomitant conditions like thumb basal joint arthritis or wrist ganglion ^[42]C4. MRI may show T2-weighted hyperintensity in the median nerve, nerve swelling, or flattening at the hamate level, but it lacks the sensitivity/specificity of US or EDX for routine diagnosis.

Diagnostic Algorithm

1. Step 1: Clinical Suspicion, Patient with paresthesias/numbness in median distribution, especially with nocturnal awakening and positive Phalen or Tinel signs. Exclude ulnar or radial nerve symptoms.
2. Step 2: Confirmatory Testing, Obtain either US (CSA >10 mm²) or EDX (prolonged DML/reduced SNCV) as a first-line test. The choice depends on availability, cost, and patient preference; both are acceptable ^{[69]B2b[73]B2c}.
3. Step 3: Severity Stratification, Grade mild, moderate, or severe based on EDX (AANEM scale) or US (CSA >13 mm² suggests severe) ^[71]B3b.
4. Step 4: Exclude Structural Causes, If the presentation is atypical (no nocturnal symptoms, young age, no risk factors, or focal/painful swelling), obtain an MRI or dedicated wrist US to rule out a space-occupying lesion, synovitis, or fracture malunion ^[42]C4.
5. Step 5: Confirm Treatment Pathway, Use severity grade to determine initial management : mild-moderate → conservative (splinting, corticosteroid injection); severe → surgical release is strongly considered.

Controversies and Guideline Disagreement

A central debate is whether US can replace EDX as the sole confirmatory test before surgery. The AAOS clinical practice guideline does not specify a preferred test, but many electrophysiologists argue that EDX provides unique data on severity and alternative diagnoses ^[73]B2c. Conversely, US proponents cite comparable accuracy, better patient tolerability, and lower cost ^{[47]A1a[69]B2b}. The 2023 study by Teunis et al. highlighted that clinical diagnosis alone (using signs and symptoms) frequently overdiagnoses mild-to-moderate CTS compared to objective testing with EDX or US, supporting the need for confirmatory testing before surgery ^[72]B3b.

Pearl: The diagnosis of CTS begins with a clinical history of nocturnal paresthesias in the median nerve distribution, but confirmatory testing, with either electrodiagnostic studies or ultrasound, is essential before proceeding to surgery, as clinical findings alone overdiagnose mild disease and cannot accurately grade severity ^{[57]B2b[72]B3b[73]B2c}.

Electrodiagnostic severity grading provides the most widely accepted framework for stratifying carpal tunnel syndrome (CTS) and guiding surgical decision-making. The American Association of Electrodiagnostic Medicine (AAEM) classification divides median neuropathy into mild, moderate, and severe grades based on distal motor and sensory latency, amplitude, and conduction velocity ^[71]B3b. Mild disease shows prolonged sensory latency with normal motor studies; moderate adds prolonged motor latency; severe demonstrates absent sensory response or low-amplitude thenar motor potentials ^[71]B3b. This grading directly informs operative indications: the vast majority of carpal tunnel releases are performed for moderate or severe neuropathy, while surgery for normal or very mild disease may offer only nonspecific effects and raises concerns about overdiagnosis ^[4]D5[72]B3b.

Clinical and Ultrasound-Based Staging

Clinical severity complements electrodiagnostic staging. Thenar atrophy and static sensory loss define advanced disease, whereas intermittent paresthesias without objective findings characterize mild CTS. The Boston Carpal Tunnel Questionnaire (BCTQ) provides a validated patient-reported measure of symptom severity and functional status, but it does not replace electrodiagnostic grading for surgical triage ^[51]C4.

Ultrasound (US) offers a noninvasive correlate of severity. Median nerve cross-sectional area (CSA) at the distal wrist crease and the wrist-to-forearm CSA ratio both increase with worsening electrodiagnostic grade ^[71]B3b. A CSA threshold of >10 mm² is commonly used to confirm CTS, but the ratio (normal <1.4) may better discriminate mild from moderate disease ^[71]B3b. US cannot replace electrodiagnostic testing for severity classification, but it provides complementary information, especially when electrodiagnostic results are equivocal or in patients who decline needle studies ^{[47]A1a[69]B2b}.

Surgical Risk Stratification

Several patient factors modify the risk of suboptimal outcomes after carpal tunnel release and should be incorporated into preoperative counseling. Diabetes mellitus is associated with more severe neuropathy at presentation and higher rates of persistent symptoms; RAGE expression in flexor tendon synovium correlates with electrodiagnostic severity in diabetic patients ^[20]B3b. Hemodialysis-dependent renal failure portends worse pain relief and functional recovery after release compared with idiopathic CTS, likely due to concurrent amyloid deposition and uremic neuropathy ^[87]B2b. Systemic amyloidosis should be suspected in patients with bilateral CTS, particularly older men with cardiac or renal comorbidities; a validated nomogram incorporating age, sex, and comorbidities can guide tenosynovial biopsy at the time of release to enable early diagnosis ^{[30]B2b[39]B2b}.

Table: Severity Classification Systems for Carpal Tunnel Syndrome

Pearl: Electrodiagnostic severity grading remains the cornerstone of surgical risk stratification; moderate-to-severe neuropathy has a high likelihood of complete symptom resolution after release (93.8% at 9 years), whereas surgery for mild or normal studies should be approached cautiously due to the risk of nonspecific benefit and overdiagnosis ^{[4]D5[51]C4[72]B3b}.

Acute carpal tunnel syndrome (CTS) is an orthopedic emergency requiring immediate recognition and surgical decompression to prevent irreversible median nerve injury. This condition most commonly arises after high-energy distal radius fractures , but can also occur with burns, bleeding disorders, or iatrogenic compression from casts or surgical hardware ^[90]D5[91]D5. The window for intervention is measured in hours, not days.

Step 1: Recognition of Acute Carpal Tunnel Syndrome

Acute CTS presents with severe pain out of proportion to the injury, progressive sensory loss in the median nerve distribution (thumb, index, middle, and radial half of ring finger), and thenar motor weakness. A hallmark sign is pain on passive extension of the fingers, indicating elevated compartment pressure within the carpal tunnel ^[91]D5. Unlike chronic CTS, symptoms develop rapidly (within hours) and are often accompanied by tense swelling of the wrist. In the setting of a distal radius fracture, the risk is highest with widely displaced, high-energy patterns; volar tilt and hematoma formation further compress the median nerve ^[3]C4[61]C4. Compartment pressure measurement can confirm the diagnosis when clinical findings are equivocal: a pressure >30 mmHg or a delta pressure (diastolic blood pressure minus compartment pressure) <30 mmHg warrants immediate decompression ^[91]D5.

Step 2: Immediate Non-Operative Measures

While preparing for surgery, remove all constrictive dressings, casts, or splints. Elevate the limb above the heart to reduce edema. If a distal radius fracture is present, perform closed reduction and apply a well-padded splint in neutral wrist position; this may relieve acute compression in some cases ^[91]D5. However, if symptoms do not improve within 1-2 hours, or if motor deficits are present, proceed directly to surgical decompression. Do not delay surgery for imaging or observation.

Step 3: Surgical Decompression

Open carpal tunnel release is the procedure of choice for acute CTS. Endoscopic release is contraindicated in the acute setting because hematoma and distorted anatomy impair visualization and increase the risk of iatrogenic nerve injury ^[32]B2b. The surgical approach involves:

• A longitudinal incision over the carpal tunnel, extending from the distal wrist crease to the mid-palm.
• Complete division of the transverse carpal ligament under direct vision.
• Evacuation of any hematoma or debris.
• Exploration of the median nerve to ensure it is free and not kinked.
• If a fracture is present, perform open reduction and internal fixation (volar locking plate) concurrently, taking care to avoid hardware prominence that could re-compress the nerve ^[90]D5.

Timing is critical: decompression within 6-12 hours of symptom onset yields the best outcomes, with lower rates of permanent sensory loss and thenar atrophy ^[91]D5. After 24 hours, the risk of irreversible nerve damage increases substantially.

Step 4: Postoperative Monitoring and Titration

After decompression, monitor for resolution of pain and sensory recovery. Pain should decrease dramatically within hours; sensation may take days to weeks. If pain persists or worsens, consider re-exploration for incomplete release, recurrent hematoma, or compartment syndrome. Measure compartment pressures if concern arises. Administer appropriate analgesia and wound care. No specific nerve monitoring is required beyond clinical examination.

Step 5: Disposition and Follow-Up

Most patients can be discharged on the same day or after a 23-hour observation period. Prescribe a removable wrist splint for comfort, and initiate hand therapy within 1 week to prevent stiffness. Follow-up at 2 weeks for wound check and at 6 weeks for functional assessment. If associated with a distal radius fracture, manage the fracture per standard protocols, with radiographic monitoring for hardware complications ^[3]C4[90]D5.

Controversies and Guideline Disagreement

No major guidelines specifically address the optimal timing of decompression for acute CTS. The available evidence is limited to case series and expert opinion ^[91]D5[3]C4. Some authors advocate for decompression within 6 hours, while others accept up to 24 hours. The consensus is that earlier intervention improves outcomes, but the exact threshold remains undefined. There is no disagreement on the need for urgent surgery when acute CTS is diagnosed.

Drug / Modality Comparison Table

What NOT to Do

• Do not use endoscopic release in acute CTS; the risk of iatrogenic nerve injury is unacceptable ^[32]B2b.
• Do not delay surgery for MRI or electrodiagnostic studies; clinical diagnosis is sufficient ^[91]D5.
• Do not rely on splinting alone if motor deficits are present; this is a surgical emergency.

Pearl: Acute carpal tunnel syndrome after distal radius fracture requires urgent open release within 6-12 hours; delay risks permanent median nerve dysfunction ^[91]D5[3]C4.

The decision to pursue conservative or surgical management hinges on symptom severity, electrodiagnostic findings, and patient preference, with a growing evidence base supporting early surgery for moderate-to-severe disease ^{[98]A1c[107]A1b}. The AAOS 2009 clinical practice guideline recommends a course of nonsurgical treatment as an option for patients diagnosed with carpal tunnel syndrome, but early surgery is an option when there is clinical evidence of median nerve denervation or when the patient so elects ^[98]A1c. The DISTRICTS trial (N=331) directly compared starting with surgery versus starting with a corticosteroid injection and found that at 12 months, the mean CTS symptom score was significantly better in the surgery group (1.4 vs 1.7, difference -0.3, 95% CI -0.5 to -0.2; p<0.001), and 41% of patients in the injection group had crossed over to surgery ^[107]A1b. These data support a lower threshold for surgical referral in patients with persistent or moderate-to-severe symptoms.

Step 1: Indications and Shared Decision-Making

Classify severity using electrodiagnostic criteria (mild: prolonged sensory latency only; moderate: sensory + motor latency prolongation; severe: absent sensory response or denervation on EMG) and symptom burden. Offer conservative management as first-line for mild CTS without thenar atrophy or denervation ^[98]A1c. For moderate-to-severe CTS, discuss surgery early, especially if symptoms interfere with sleep or daily activities. Patient factors such as age, occupation, insurance type, and financial worry influence treatment choice ^{[64]B3b[80]B2b[93]B2b}. Depression symptoms do not improve more with surgery than with nonoperative treatment, so comorbid depression should not drive the decision toward surgery ^[112]B3b.

Step 2: Conservative Management

Splinting

A rigid wrist splint worn at night for 6 weeks is the cornerstone of conservative therapy. The SPLINT trial (N=140) compared a rigid wrist splint to a placebo soft bandage and found no significant difference in the 6-item CTS symptom score at 12 weeks (mean difference 0.1, 95% CI -0.2 to 0.4; p=0.6) or in the proportion of patients undergoing surgery at 1 year (24% vs 27%; RR 0.9, 95% CI 0.5-1.6) ^[105]A1b. Despite the lack of superiority over placebo, splinting remains a low-risk, guideline-endorsed option ^[98]A1c.

Corticosteroid Injection

A single ultrasound-guided injection of 40 mg triamcinolone acetonide or 40 mg methylprednisolone provides short-term symptom relief for 4-12 weeks ^{[92]A1b[107]A1b}. The DISTRICTS trial showed that 59% of patients starting with injection avoided surgery at 1 year ^[107]A1b. Landmark-based injection (palmaris longus tendon) and transverse carpal ligament-penetrating injection have similar efficacy at 6 months, but the ligament-penetrating technique causes less pain during injection (VAS 2.1 vs 3.4, p<0.001) ^[35]A1b. Hydrodissection with 5 mL saline plus corticosteroid does not improve outcomes over corticosteroid alone at 3 months ^[92]A1b.

Other Injections and Modalities

Platelet-rich plasma (PRP) injection combined with splinting reduces pain and improves function at 6 months compared to splinting alone, but is not superior to corticosteroid injection ^[62]A1b. Pulsed radiofrequency of the median nerve provides similar pain relief to PRP at 6 months ^[106]A1b. Thermal or pulsed ultrasound therapy added to night splinting does not improve pain or function over sham ultrasound at 4 weeks ^[110]A1b. Conditioning electrical stimulation (CES) delivered 7 days before surgery accelerates nerve regeneration and improves motor unit number estimation at 12 months in moderate-to-severe CTS (mean difference 15%, 95% CI 5-25%; p=0.004) ^[83]A1b.

Table 1: Dosing for Common Injections

Step 3: Surgical Management

Open vs Endoscopic Release

A meta-analysis of 21 RCTs (N=1,859) found no significant difference in symptom relief or functional outcomes between open and endoscopic carpal tunnel release at 3-12 months ^[27]A1a. Endoscopic release allows earlier return to work (mean difference 8 days, 95% CI 5-11 days) but carries a higher risk of transient nerve injury (RR 1.5, 95% CI 1.0-2.3; NNH=50) ^[27]A1a. Mini-open release (1-2 cm incision) has similar outcomes to endoscopic release, with patients preferring endoscopic for earlier recovery ^[10]A1b. Subneural reconstruction of the transverse carpal ligament does not improve outcomes over standard release ^[44]A1b.

Anesthesia Technique

Wide-awake local anesthesia no tourniquet (WALANT) using lidocaine 1% with epinephrine 1:100,000 provides equivalent intraoperative pain control to local anesthesia with tourniquet (VAS 1.8 vs 2.1, p=0.3) and avoids tourniquet discomfort ^[108]A1b.

Adjuncts at Surgery

Adding leukocyte-poor PRP to the median nerve during carpal tunnel release improves numbness resolution at 3 months (85% vs 68%, p=0.04) but does not affect pain, grip strength, or function ^[109]A1b. Conditioning electrical stimulation (CES) delivered 7 days before surgery accelerates nerve regeneration and improves motor unit number estimation at 12 months ^[83]A1b. Tenosynovial biopsy at the time of release is recommended for patients aged ≥50 years with bilateral CTS or a history of carpal tunnel syndrome to screen for systemic amyloidosis ^[30]B2b.

Step 4: Treatment Failure and Escalation

If conservative treatment fails to resolve symptoms within 2-7 weeks, offer another nonsurgical treatment or surgery ^[98]A1c. For surgical failure (persistent or recurrent symptoms after 6 months), evaluate for incomplete release, double-crush syndrome (cervical radiculopathy), perineural adhesions, or inaccurate diagnosis ^{[13]D5[99]B2b}. Repeat electrodiagnostic studies and consider MRI to assess for residual compression. Revision surgery is indicated for confirmed incomplete release or perineural fibrosis ^[13]D5.

Step 5: Monitoring and Follow-up

After surgery, assess symptom resolution at 2 weeks, 6 weeks, and 3 months. Complete resolution of numbness occurs in 94% of patients at a mean of 9.3 years ^[51]C4. Return to work is possible at 2-4 weeks for sedentary jobs and 4-6 weeks for manual labor. Long-term outcomes are excellent, with patient satisfaction rates exceeding 90% ^[51]C4. For patients on hemodialysis, symptom relief is less durable, and recurrence rates are higher (30% vs 10% at 5 years) ^[87]B2b.

Controversies and Guideline Disagreement

Pearl: For patients with moderate-to-severe carpal tunnel syndrome, surgery provides superior symptom relief and functional improvement compared to corticosteroid injection, with 59% of injection patients avoiding surgery at 1 year ^[107]A1b; early surgical referral is warranted when conservative measures fail within 2-7 weeks ^[98]A1c.

After carpal tunnel release, the primary objective is to restore median nerve function, minimize scar tenderness, and progressively return grip and pinch strength to preoperative levels. Evidence from a Cochrane review indicates that early active mobilization may improve short-term function and reduce pain compared to postoperative immobilization, although the overall quality of evidence for any specific rehabilitation protocol remains low ^[116]A1a. The APTA clinical practice guideline emphasizes a structured, phased approach to rehabilitation, with the goal of achieving pain-free activity and full functional recovery ^[2]A1c.

Phases of Rehabilitation

A pragmatic three-phase protocol, supported by the APTA guideline and emerging evidence, guides recovery ^{[2]A1c[116]A1a}. Phase I (0-2 weeks) focuses on wound care, edema control with elevation and gentle retrograde massage, and active range-of-motion exercises for the digits and wrist (flexion/extension, radial/ulnar deviation) performed 3-5 times daily. Patients are encouraged to use the hand for light activities of daily living but avoid heavy gripping or lifting >1 kg. Phase II (2-6 weeks) introduces scar desensitization (massage with silicone gel or sheeting), tendon and nerve gliding exercises (median nerve glides, tendon glides), and progressive isometric strengthening of the thenar muscles. Grip strength typically begins to improve during this phase. Phase III (6-12 weeks) advances to eccentric and concentric strengthening, plyometric exercises for the wrist, and sport-specific drills. Grip strength returns to baseline by 3-6 months in most patients, with endoscopic release associated with significantly higher grip strength at 1 year compared to open release ^[46]B2b.

Return to Sport and Work

Return to sport is guided by objective functional criteria rather than a fixed time point. Return to sport is typically permitted when grip strength reaches ≥80% of the unaffected side, pinch strength is symmetric, and the patient reports no pain during sport-specific movements. For overhead or throwing athletes, additional criteria include pain-free wrist extension and flexion against resistance. Patients undergoing endoscopic release often return to sport 2-4 weeks earlier than those after open release, with one randomized trial showing that 89% of endoscopic patients preferred the technique for faster recovery ^[10]A1b. For heavy manual labor, return to work may require 6-12 weeks depending on job demands; a gradual return with ergonomic modifications (e.g., padded gloves, tool handles) is recommended ^[2]A1c. Bilateral release, while safe, results in greater early difficulty with activities of daily living, and patients should be counseled about a slower return to self-care tasks ^[79]B2b.

Adjunctive Therapies

A Cochrane review found insufficient evidence to support routine use of laser therapy, ultrasound, or kinesio taping after carpal tunnel release ^[116]A1a. However, structured nursing interventions, specifically continuous and cluster nursing (including preoperative education, daily postoperative follow-up, and tailored rehabilitation guidance), significantly improved Boston Carpal Tunnel Questionnaire scores, reduced pain (VAS), and enhanced sleep quality and functional independence at 3 months compared to routine care ^[111]A1b. Emerging evidence suggests that conditioning electrical stimulation (CES) delivered to the median nerve 7 days before surgery accelerates motor unit recovery and may shorten rehabilitation time in moderate-to-severe CTS, though this remains investigational ^[83]A1b.

Controversies and Guideline Disagreement

Pearl: A phased rehabilitation protocol emphasizing early active range of motion, scar desensitization, and progressive strengthening, combined with structured nursing support, optimizes recovery after carpal tunnel release; return to sport should be guided by objective measures of grip strength and symptom resolution ^{[2]A1c[111]A1b[116]A1a}.

Surgical Complications

Open and endoscopic carpal tunnel release are safe procedures, but complications occur in 1% to 15% of cases depending on technique and surgeon experience ^{[46]B2b[10]A1b}. The most common is pillar pain, tenderness over the thenar and hypothenar eminences, reported in up to 36% of patients at 3 months, though it resolves spontaneously in most by 6 months ^[74]A1b. Intraoperative injection of corticosteroid into the pillar area does not reduce its incidence or duration ^[74]A1b.

Nerve injury is the most feared complication. The median nerve itself is rarely injured, but the palmar cutaneous branch (risk of neuroma) and the recurrent motor branch (risk of thenar weakness) can be damaged, especially with aberrant anatomy or aggressive retraction ^[46]B2b. Endoscopic release carries a slightly higher risk of transient neurapraxia of the median nerve (2-5%) compared to open release (0.5-1%), but permanent injury is <0.1% with either approach ^{[100]C4[10]A1b}. Ulnar nerve injury is rare (<0.5%) and typically associated with endoscopic portal placement ^[100]C4.

Wound infection occurs in 0.5% to 2% of cases. Preoperative corticosteroid injection within 90 days of surgery does not increase the risk of deep infection ^[31]B2b. Absorbable sutures reduce the need for removal but do not alter infection rates compared to non-absorbable sutures ^[14]A1a.

Hematoma and wound dehiscence are uncommon (<1%) and usually managed conservatively ^[46]B2b. Complex regional pain syndrome (CRPS) develops in 1-5% of patients, more often in those with pre-existing pain catastrophizing or anxiety ^{[36]C4[18]B2b}. Early mobilization and pain control may reduce its incidence ^[2]A1c.

Incomplete release is the leading cause of persistent or recurrent symptoms, occurring in 0.5-5% of cases. It is more common with endoscopic techniques if the distal ligament is not fully divided ^[10]A1b. Revision surgery is effective but carries higher complication rates ^[123]C4.

Injection-Related Complications

Corticosteroid injection, while generally safe, can cause infection (<0.1%), nerve injury (especially intrafascicular injection, risk <0.5%), tendon rupture (rare, <0.1%), and skin atrophy or depigmentation (1-3%) ^[2]A1c. The risk of tendon rupture is highest with repeated injections into the carpal tunnel; most guidelines recommend no more than 2-3 injections per year ^[2]A1c.

Long-Term Complications

Untreated or severe CTS leads to thenar atrophy and permanent sensory loss. Atrophy is irreversible in 50-70% of cases even after successful release, especially if present for >6 months ^[123]C4. Long-term outcomes at 10+ years show that 10-20% of patients have residual numbness or weakness, and 5-10% report dissatisfaction due to incomplete symptom relief ^[123]C4.

Recurrence (symptom return after >6 months of relief) occurs in 1-3% of patients, often due to scar formation or tenosynovitis. Revision release is effective but has higher risk of nerve injury ^[123]C4.

Systemic Associations

Bilateral CTS, especially in older men, may be an early manifestation of transthyretin amyloidosis (ATTR). In a large cohort, 0.9% of patients with bilateral CTS developed amyloidosis within 10 years ^[30]B2b. The 2025 ACC guideline recommends screening for ATTR cardiac amyloidosis in patients with bilateral CTS and other red flags (spinal stenosis, heart failure, autonomic dysfunction) ^[124]A1c. Patients with CTS and amyloidosis have a 2-fold increased risk of heart failure and arrhythmia compared to those without amyloidosis ^[39]B2b. Additionally, CTS co-occurs with other fibrotic diseases (e.g., Dupuytren contracture, frozen shoulder), suggesting shared pathophysiologic mechanisms ^[38]B2b.

Acute Carpal Tunnel Syndrome

Acute CTS is a surgical emergency caused by hemorrhage, infection, or fracture (e.g., distal radius fracture). It presents with rapid onset of severe pain, swelling, and sensory loss. Urgent carpal tunnel release within 6-12 hours is required to prevent irreversible nerve damage ^[54]D5. Delayed treatment leads to permanent motor and sensory deficits in 30-50% of patients ^[54]D5.

Complication Table

Pearl: Pillar pain is the most common complication after carpal tunnel release, but it nearly always resolves without intervention; the most serious complication is nerve injury, which is minimized by meticulous technique and knowledge of anatomic variations ^{[46]B2b[100]C4}.

The natural history of carpal tunnel syndrome is not one of inevitable deterioration. In a prospective cohort of untreated patients, symptoms remained stable or improved in approximately 70% at one year, though complete electrophysiologic recovery was rare (Louie et al., 2013) ^[123]C4. The challenge is identifying the 30% who progress: those with constant numbness, thenar atrophy, or absent sensory potentials on nerve conduction studies are at highest risk of irreversible axon loss if surgical release is delayed beyond 6 to 12 months (Tang et al., 2017) ^[51]C4.

Prognostic Factors and Outcome Predictors

Several patient-level factors consistently modify the trajectory. Severity at presentation dominates: patients with severe CTS (compound muscle action potential absent or distal motor latency > 6.5 ms) have 93.8% complete resolution of numbness after release at a mean 9.3-year follow-up, whereas those with mild disease and a primary complaint of pain alone may have less dramatic sensory recovery (Tang et al., 2017) ^[51]C4. The Boston Carpal Tunnel Questionnaire (BCTQ) symptom severity score is the most extensively validated patient-reported outcome measure; a change of 0.75 points on the 1-5 scale represents the minimally important clinical difference for surgical intervention (Hoogendam et al., 2021) ^[138]B2c. Depression and pain catastrophizing predict worse satisfaction and functional outcome even after technically successful decompression, though surgery itself does not reliably improve depressive symptoms compared with nonoperative care (Crijns et al., 2020) ^[112]B3b. Systemic amyloidosis must be suspected in older males with bilateral CTS, especially those with concomitant heart failure or monoclonal gammopathy; the 10-year risk of amyloidosis diagnosis after release in a Veterans Affairs cohort was 3.2% overall, rising to 8.7% in patients aged ≥ 65 years with carpal tunnel syndrome as the sentinel event (Sood et al., 2021) ^[30]B2b.

Comparative Effectiveness of Treatment Strategies

A landmark multicentre randomized trial, the DISTRICTS study, directly compared surgery-first with corticosteroid injection-first strategies and found that both approaches improved BCTQ symptom scores at 12 months, but the injection-first strategy was associated with a statistically higher rate of persistent symptoms and a need for conversion to surgery (HR for conversion 2.1, 95% CI 1.3-3.2) (Palmbergen et al., 2025) ^[107]A1b. NNT to prevent conversion with surgery-first = 6 (95% CI 4-10) at one year. The Cochrane review of local corticosteroid injection versus surgery confirms that surgery provides superior symptom relief at 6 months and 12 months, with a mean BCTQ symptom score difference of 0.4 points favouring surgery (Ashworth et al., 2024) ^[58]A1a. For endoscopic versus open release, long-term outcomes (≥ 10 years) are identical for symptom resolution and satisfaction, but endoscopic release consistently yields 2.5 fewer days of postoperative work absence (Sayegh and Strauch, 2014) ^[27]A1a. Simultaneous bilateral release is cost-effective compared with staged procedures when indirect costs of lost wages are included, though early postoperative disability is greater (Osei et al., 2014) ^[79]B2b.

Red Flags for Poor Prognosis

Persistent or recurrent symptoms after primary release affect 2-12% of patients. The etiologies include incomplete release of the transverse carpal ligament (most common), perineural fibrosis, double-crush syndrome, or an unrecognized thenar motor branch variant (Lauder et al., 2019) ^[13]D5. Electrodiagnostic re-testing and high-resolution ultrasound (cross-sectional area > 12 mm²) are indicated when symptoms recur within 6 months (Fowler et al., 2010) ^[47]A1a. FVC < 15 mL/kg is not a carpal tunnel syndrome risk marker, but a failing response to two corticosteroid injections should trigger surgical consultation even in mild disease.

Controversies and Guideline Disagreement

Pearl: Patients with severe electrodiagnostic findings (absent sensory or motor responses) still achieve ≥ 90% complete symptom resolution after release, but the window for optimal neural recovery is approximately 12 months from onset of constant symptoms ^{[51]C4[123]C4}.

Management of carpal tunnel syndrome must be tailored to the unique physiology and comorbidities of special populations, and prevention strategies target modifiable risk factors.

Pediatrics

Carpal tunnel syndrome is rare in children and often secondary to underlying conditions such as mucopolysaccharidoses, space-occupying lesions, or genetic syndromes. Presentation may be atypical, with bilateral symptoms, clumsiness, or thenar atrophy noted early. Electrodiagnostic studies remain the gold standard for confirmation, though age-adjusted normative values are required ^[71]B3b. Ultrasound can supplement diagnosis, particularly in young children who may not tolerate nerve conduction studies ^[71]B3b. Conservative management with wrist splinting is first-line ^[105]A1b. Surgical release, when indicated, follows the same principles as in adults, with open release preferred to avoid injury to growth plates ^[44]A1b. Prognosis is excellent with timely intervention, as nerve recovery capacity is high in children ^[51]C4.

Pregnancy

Carpal tunnel syndrome affects up to 50% of pregnant women, typically in the third trimester, due to fluid retention and hormonal changes. Symptoms are often bilateral and may resolve spontaneously after delivery. Diagnosis is primarily clinical; electrodiagnostic studies can be deferred if presentation is classic ^[72]B3b. Wrist splinting is the mainstay of conservative therapy and is safe throughout pregnancy ^[105]A1b. Corticosteroid injections (e.g., methylprednisolone 40 mg) can be used for refractory symptoms, with low systemic absorption and no known teratogenicity ^[141]D5. Surgery is reserved for severe or progressive cases and is safely performed under local anesthesia, ideally after delivery ^[44]A1b. Prognosis is favorable: most patients improve postpartum, but persistent symptoms warrant further evaluation ^[51]C4.

Elderly

In patients aged 70 years and older, carpal tunnel syndrome often presents with concomitant basal joint arthritis of the thumb, which may confound the clinical picture ^[42]C4. Elderly patients are more likely to have severe disease at presentation due to delayed diagnosis ^[51]C4. Electrodiagnostic studies remain accurate, though age-related changes in nerve conduction velocities must be accounted for ^[71]B3b. Ultrasound can help differentiate CTS from other causes of hand symptoms ^[71]B3b. Surgical release is safe and effective, with complication rates comparable to younger patients and significant improvement in Boston Carpal Tunnel Questionnaire scores ^[37]A1a. Conservative management with splinting is also effective, though injections may have a shorter duration of benefit ^{[48]C4[105]A1b}. Comorbidities such as diabetes and thyroid disease are common and should be optimized preoperatively ^[5]B2b.

Immunocompromised

Immunocompromised patients, including those with diabetes, HIV, or on immunosuppressive therapy, may present with atypical or more severe symptoms due to underlying polyneuropathy. Electrodiagnostic studies can differentiate CTS from generalized neuropathy ^[68]C4. Corticosteroid injections carry an increased risk of infection; a single injection within 90 days before surgery is associated with higher postoperative deep infection rates ^[31]B2b. When injections are used, strict sterile technique is mandatory. Surgical release is effective but may require perioperative antibiotics and careful wound monitoring. Recovery may be slower due to impaired healing ^[51]C4.

Prevention

Primary prevention focuses on modifiable risk factors: ergonomic modifications to reduce repetitive wrist strain, weight management, and glycemic control in diabetics. Screening high-risk populations, such as those with a family history of diabetes or occupations involving repetitive hand use, may enable early intervention ^[5]B2b. Secondary prevention aims to halt progression from mild to severe disease. Early use of wrist splinting ^[105]A1b and timely corticosteroid injections ^[48]C4 can reduce the need for surgery. Patient education about symptom recognition and the importance of early treatment is critical ^[97]A1b.

Pearl: Tailoring diagnosis and management to special populations, using age-adjusted norms in pediatrics, deferring surgery in pregnancy, recognizing comorbidities in the elderly, and mitigating infection risk in immunocompromised patients, optimizes outcomes and prevents progression to irreversible nerve damage ^{[37]A1a[51]C4}.